Efficacy of DNA Vaccination against Western Equine Encephalitis Virus Infection

PDF

Authors
  1. Nagata, L.P.
  2. Hu, W-G.
  3. Masri, S.A.
  4. Rayner, G.A.
  5. Schmaltz, F.L.
  6. Das, D.
  7. Wu, J.
  8. Long, M.C.
  9. Chan, C.
  10. Proll, D.
  11. Jager, S.
  12. JeBailey, L.
Corporate Authors
Defence R&D Canada - Suffield, Ralston ALTA (CAN)
Abstract
The efficacy of a DNA vaccine against western equine encephalitis (WEE) infection in mice was evaluated. The 26S structural region was expressed, in vitro from an internal T7 promoter using a rabbit reticulysate transcription/translation system; and from a CMV promoter after transfection into Vero cell monolayers. The proteins synthesized were reactive with anti-WEE virus (WEEV) antibodies, both in western blot analysis and histochemical staining, respectively. When the DNA vaccine plasmid, pVHX-6, was administered intraepidermally to mice, followed by challenge in a lethal mouse model, the level of protection obtained ranged from 50 to 100% amongst three strains of WEEV. Preliminary results suggest the protective immunity provided by the DNA vaccine appears to be a cell-mediated immune response, as elevated cytotoxic T lymphocyte activity was detected against the E2 protein in a T-cell proliferation assay. The efficacy results suggest a DNA vaccine may be a promising approach against WEE infection.
Keywords
Genetic analysis;Recombinant antibody technology;WEEV (Western Equine Encephalitis Virus);Genetic engineering
Report Number
DRDC-SUFFIELD-SL-2002-151 — Scientific Literature
Date of publication
10 May 2005
Number of Pages
4
Reprinted from
Science Direct, vol 23, 2005, p 2280-2283
DSTKIM No
CA025802
CANDIS No
523518
Format(s):
Hardcopy;Document Image stored on Optical Disk

Permanent link

Document 1 of 1

Date modified: